share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

诺和诺德 | 6-K：诺和诺德-股票回购计划
美股sec公告 ·  06/17 09:05
Moomoo AI 已提取核心信息
On June 17, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over a 12-month period starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7, 2024, and August 5, 2024. As of June 14, 2024, Novo Nordisk has repurchased 9,703,295 B shares at an average price of DKK 868.99 per share, totaling DKK 8,432,046,688. The transactions are in line with the Safe Harbour Rules of the European Union. Following these transactions, Novo Nordisk holds 11,068,859 B shares as treasury shares, which is 0.2% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
On June 17, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over a 12-month period starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7, 2024, and August 5, 2024. As of June 14, 2024, Novo Nordisk has repurchased 9,703,295 B shares at an average price of DKK 868.99 per share, totaling DKK 8,432,046,688. The transactions are in line with the Safe Harbour Rules of the European Union. Following these transactions, Novo Nordisk holds 11,068,859 B shares as treasury shares, which is 0.2% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
2024年6月17日，全球领先的医疗保健公司诺和诺德（Novo Nordisk A/S）宣布在其股票回购计划中取得了进展，该计划是一项价值200亿丹麦克朗的更大规模回购计划的一部分，该计划将在2024年2月6日开始的12个月内进行，该公司在2024年5月7日至2024年8月5日期间回购了总数约为22亿丹麦克朗的B类股票。截至2024年6月14日，诺和诺德已以868.99丹麦克朗的平均价格回购9703295股B类股票，总价值达8,432,046,688丹麦克朗，该交易符合欧盟安全港规则。此次交易后，诺和诺德持有11068859股B类股票作为库存，占该公司股本的0.2%。该公司的总股数（包括库存股份）为44.65亿股A股和B股。诺和诺德的股票在纳斯达克哥本哈根交易所上市，其美国存托股票在纽约证券交易所上市。
2024年6月17日，全球领先的医疗保健公司诺和诺德（Novo Nordisk A/S）宣布在其股票回购计划中取得了进展，该计划是一项价值200亿丹麦克朗的更大规模回购计划的一部分，该计划将在2024年2月6日开始的12个月内进行，该公司在2024年5月7日至2024年8月5日期间回购了总数约为22亿丹麦克朗的B类股票。截至2024年6月14日，诺和诺德已以868.99丹麦克朗的平均价格回购9703295股B类股票，总价值达8,432,046,688丹麦克朗，该交易符合欧盟安全港规则。此次交易后，诺和诺德持有11068859股B类股票作为库存，占该公司股本的0.2%。该公司的总股数（包括库存股份）为44.65亿股A股和B股。诺和诺德的股票在纳斯达克哥本哈根交易所上市，其美国存托股票在纽约证券交易所上市。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息